Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Carney DA"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-12 z 12
    Tytuł:
    Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy.
    Autorzy:
    Lew TE; a Faculty of Medicine, Nursing and Health Sciences , Monash University , Clayton , Australia ;
    Cheah CY; b Department of Hematology , Peter MacCallum Cancer Centre , East Melbourne , Australia ;; c University of Melbourne , Parkville , Australia ;
    Carney DA; b Department of Hematology , Peter MacCallum Cancer Centre , East Melbourne , Australia ;; c University of Melbourne , Parkville , Australia ;
    Prince HM; b Department of Hematology , Peter MacCallum Cancer Centre , East Melbourne , Australia ;; c University of Melbourne , Parkville , Australia ;
    Wolf M; b Department of Hematology , Peter MacCallum Cancer Centre , East Melbourne , Australia ;; c University of Melbourne , Parkville , Australia ;
    Bazargan A; d Department of Hematology , St Vincent's Hospital , Fitzroy , Australia.
    Januszewicz EH; b Department of Hematology , Peter MacCallum Cancer Centre , East Melbourne , Australia ;
    Filshie R; d Department of Hematology , St Vincent's Hospital , Fitzroy , Australia.
    Westerman D; b Department of Hematology , Peter MacCallum Cancer Centre , East Melbourne , Australia ;
    Seymour JF; b Department of Hematology , Peter MacCallum Cancer Centre , East Melbourne , Australia ;; c University of Melbourne , Parkville , Australia ;
    Tam CS; b Department of Hematology , Peter MacCallum Cancer Centre , East Melbourne , Australia ;; c University of Melbourne , Parkville , Australia ;
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2016 May; Vol. 57 (5), pp. 1044-53. Date of Electronic Publication: 2015 Nov 20.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
    Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/administration & dosage ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Male ; Neoplasm Staging ; Rituximab/administration & dosage ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review.
    Autorzy:
    Cheah CY; Department of Haematology, Peter MacCallum Cancer Centre , East Melbourne, Victoria , Australia.
    Hofman MS
    Seymour JF
    Ritchie DS
    Dickinson M
    Wirth A
    Prince HM
    Wolf M
    Januszcewicz EH
    Carney DA
    Herbert KE
    Harrison SJ
    Burbury KL
    Tam CS
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2015 Jan; Vol. 56 (1), pp. 49-56. Date of Electronic Publication: 2014 Jun 16.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Fluorodeoxyglucose F18*
    Positron-Emission Tomography*
    Tomography, X-Ray Computed*
    Lymphoma, B-Cell/*diagnosis
    Mediastinal Neoplasms/*diagnosis
    Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Female ; Humans ; Image Interpretation, Computer-Assisted ; Lymphoma, B-Cell/mortality ; Lymphoma, B-Cell/therapy ; Male ; Mediastinal Neoplasms/mortality ; Mediastinal Neoplasms/therapy ; Middle Aged ; Neoplasm Recurrence, Local ; Patient Outcome Assessment ; Prognosis ; Radiotherapy ; Retrospective Studies ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
    Autorzy:
    Cheah CY; 1] Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
    Herbert KE; 1] Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia [3] Cabrini Medical Centre, Malvern, Victoria, Australia.
    O'Rourke K; Department of Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
    Kennedy GA; 1] Department of Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia [2] University of Queensland, St Lucia, Queensland, Australia.
    George A; Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia.
    Fedele PL; Department of Haematology, Monash Health, Clayton, Victoria, Australia.
    Gilbertson M; 1] Department of Haematology, Monash Health, Clayton, Victoria, Australia [2] Department of Haematology, Monash University, Clayton, Victoria, Australia.
    Tan SY; Department of Haematology, Monash Health, Clayton, Victoria, Australia.
    Ritchie DS; 1] Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
    Opat SS; 1] Department of Haematology, Monash Health, Clayton, Victoria, Australia [2] Department of Haematology, Monash University, Clayton, Victoria, Australia.
    Prince HM; 1] Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia [3] Cabrini Medical Centre, Malvern, Victoria, Australia [4] Department of Haematology, Monash University, Clayton, Victoria, Australia.
    Dickinson M; 1] Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
    Burbury K; 1] Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
    Wolf M; 1] Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia [3] Cabrini Medical Centre, Malvern, Victoria, Australia.
    Januszewicz EH; Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia.
    Tam CS; 1] Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
    Westerman DA; 1] Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
    Carney DA; 1] Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
    Harrison SJ; 1] Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
    Seymour JF; 1] Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
    Pokaż więcej
    Źródło:
    British journal of cancer [Br J Cancer] 2014 Sep 09; Vol. 111 (6), pp. 1072-9. Date of Electronic Publication: 2014 Jul 29.
    Typ publikacji:
    Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Central Nervous System Neoplasms/*prevention & control
    Lymphoma, Large B-Cell, Diffuse/*drug therapy
    Methotrexate/*administration & dosage
    Acute Kidney Injury/chemically induced ; Administration, Intravenous ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Central Nervous System Neoplasms/secondary ; Cyclophosphamide/administration & dosage ; Cytarabine/administration & dosage ; Dexamethasone/administration & dosage ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Etoposide/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Ifosfamide/administration & dosage ; Injections, Spinal ; Lymphoma, Large B-Cell, Diffuse/pathology ; Male ; Methotrexate/adverse effects ; Middle Aged ; Prednisone/administration & dosage ; Recurrence ; Retrospective Studies ; Risk Assessment ; Rituximab ; Survival Rate ; Vincristine/administration & dosage ; Young Adult
    SCR Protocol:
    CVAD protocol; IVAC protocol
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    All is not lost--the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab.
    Autorzy:
    Cheah CY
    Lew TE
    Lee R
    Tam CS
    Seymour JF
    Carney DA
    Pokaż więcej
    Źródło:
    European journal of haematology [Eur J Haematol] 2013 Aug; Vol. 91 (2), pp. 189-90. Date of Electronic Publication: 2013 Jun 28.
    Typ publikacji:
    Letter; Comment
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
    Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
    Leukemia, Lymphocytic, Chronic, B-Cell/*mortality
    Female ; Humans ; Male
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy.
    Autorzy:
    Cheah CY; Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.
    Hofman MS
    Dickinson M
    Wirth A
    Westerman D
    Harrison SJ
    Burbury K
    Wolf M
    Januszewicz H
    Herbert K
    Prince HM
    Carney DA
    Ritchie DS
    Hicks RJ
    Seymour JF
    Pokaż więcej
    Źródło:
    British journal of cancer [Br J Cancer] 2013 Jul 23; Vol. 109 (2), pp. 312-7. Date of Electronic Publication: 2013 Jun 27.
    Typ publikacji:
    Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Positron-Emission Tomography*
    Tomography, X-Ray Computed*
    Lymphoma, Large B-Cell, Diffuse/*diagnostic imaging
    Monitoring, Physiologic/*methods
    Multimodal Imaging/*methods
    Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/metabolism ; Female ; Humans ; Lymphoma, Large B-Cell, Diffuse/metabolism ; Lymphoma, Large B-Cell, Diffuse/therapy ; Male ; Middle Aged ; Monitoring, Physiologic/statistics & numerical data ; Multimodal Imaging/statistics & numerical data ; Neoadjuvant Therapy ; Predictive Value of Tests ; Prognosis ; Remission Induction ; Retrospective Studies ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    No evidence for DNA methylation of the ATM promoter CpG island in chronic lymphocytic leukemia.
    Autorzy:
    Mikeska T
    Carney DA
    Seymour JF
    Dobrovic A
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2012 Jul; Vol. 53 (7), pp. 1420-2. Date of Electronic Publication: 2012 Jan 31.
    Typ publikacji:
    Letter; Research Support, Non-U.S. Gov't
    MeSH Terms:
    DNA Methylation*
    Cell Cycle Proteins/*genetics
    CpG Islands/*genetics
    DNA-Binding Proteins/*genetics
    Leukemia, Lymphocytic, Chronic, B-Cell/*genetics
    Promoter Regions, Genetic/*genetics
    Protein Serine-Threonine Kinases/*genetics
    Tumor Suppressor Proteins/*genetics
    Adult ; Aged ; Ataxia Telangiectasia Mutated Proteins ; Cell Line, Tumor ; Female ; HCT116 Cells ; Humans ; Male ; Middle Aged ; Polymerase Chain Reaction/methods
    Raport
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting analysis.
    Autorzy:
    Tan AY
    Wong SQ
    Nyvold CG
    Carney DA
    Wei A
    Seymour JF
    Hokland P
    Westerman
    Dobrovic A
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2012 Jun; Vol. 53 (6), pp. 1225-9. Date of Electronic Publication: 2012 Jan 13.
    Typ publikacji:
    Evaluation Study; Letter; Validation Study
    MeSH Terms:
    Mutation*/physiology
    DNA Mutational Analysis/*methods
    Leukemia, Myeloid, Acute/*genetics
    fms-Like Tyrosine Kinase 3/*genetics
    Adult ; Aged ; Aged, 80 and over ; Catalytic Domain/genetics ; Exons/genetics ; Female ; Humans ; Infant ; Infant, Newborn ; Leukemia, Myeloid, Acute/diagnosis ; Male ; Middle Aged ; Nucleic Acid Denaturation/genetics ; Protein-Tyrosine Kinases/chemistry ; Protein-Tyrosine Kinases/genetics ; Time Factors ; fms-Like Tyrosine Kinase 3/analysis ; fms-Like Tyrosine Kinase 3/chemistry
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
    Autorzy:
    Gangatharan SA
    Carney DA
    Campbell LJ
    Prince HM
    Kenealy MK
    Seymour JF
    Pokaż więcej
    Źródło:
    European journal of haematology [Eur J Haematol] 2011 Aug; Vol. 87 (2), pp. 186-8.
    Typ publikacji:
    Case Reports; Letter
    MeSH Terms:
    Azacitidine/*therapeutic use
    Myelodysplastic Syndromes/*drug therapy
    Myelodysplastic Syndromes/*genetics
    Aged ; Antimetabolites, Antineoplastic/therapeutic use ; Cytogenetic Analysis ; Humans ; Middle Aged ; Treatment Outcome
    Raport
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
    Autorzy:
    Carney DA; Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, Australia. dennis.carney@petermac.org
    Westerman DA
    Tam CS
    Milner A
    Prince HM
    Kenealy M
    Wolf M
    Januszewicz EH
    Ritchie D
    Came N
    Seymour JF
    Pokaż więcej
    Źródło:
    Leukemia [Leukemia] 2010 Dec; Vol. 24 (12), pp. 2056-62. Date of Electronic Publication: 2010 Oct 21.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Antineoplastic Agents/*adverse effects
    Leukemia, Myeloid, Acute/*chemically induced
    Myelodysplastic Syndromes/*chemically induced
    Neoplasms, Second Primary/*chemically induced
    Vidarabine/*analogs & derivatives
    Adult ; Aged ; Aged, 80 and over ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/therapy ; Male ; Middle Aged ; Myelodysplastic Syndromes/mortality ; Myelodysplastic Syndromes/therapy ; Vidarabine/adverse effects
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?
    Autorzy:
    Carney DA; Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Australia. dennis.carney@petermac.org
    Seymour JF
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2010 Nov; Vol. 51 (11), pp. 1957-9. Date of Electronic Publication: 2010 Sep 21.
    Typ publikacji:
    Evaluation Study; Journal Article; Comment
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*adverse effects
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Leukemia, Myeloid, Acute/*drug therapy
    Myelodysplastic Syndromes/*chemically induced
    Vidarabine/*analogs & derivatives
    Humans ; Neoplasms, Second Primary/chemically induced ; Risk Assessment ; Vidarabine/administration & dosage ; Vidarabine/adverse effects
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator.
    Autorzy:
    Herbert KE; Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
    Morgan S
    Prince HM
    Westerman DA
    Wolf MM
    Carney DA
    Yuen K
    di Iulio J
    Seymour JF
    Pokaż więcej
    Źródło:
    Leukemia [Leukemia] 2009 Feb; Vol. 23 (2), pp. 305-12. Date of Electronic Publication: 2008 Nov 06.
    Typ publikacji:
    Clinical Trial, Phase II; Journal Article
    MeSH Terms:
    Granulocyte Colony-Stimulating Factor/*administration & dosage
    Hematopoietic Stem Cell Mobilization/*methods
    Lymphoproliferative Disorders/*drug therapy
    Stem Cell Factor/*administration & dosage
    Vidarabine/*analogs & derivatives
    Adult ; Aged ; Cell Count ; Female ; Filgrastim ; Hematopoietic Stem Cells/cytology ; Hematopoietic Stem Cells/drug effects ; Humans ; Male ; Middle Aged ; Recombinant Proteins ; Treatment Outcome ; Vidarabine/therapeutic use
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.
    Autorzy:
    Carney DA; Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. dennis.carney@petermac.org
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2008 Oct; Vol. 49 (10), pp. 1846-51.
    Typ publikacji:
    Journal Article; Review
    MeSH Terms:
    Arsenicals/*pharmacology
    Leukemia, Promyelocytic, Acute/*drug therapy
    Oxides/*pharmacology
    Arsenic Trioxide ; Arsenicals/therapeutic use ; Cell Differentiation/drug effects ; Cell Proliferation/drug effects ; Humans ; Leukemia, Promyelocytic, Acute/metabolism ; Leukemia, Promyelocytic, Acute/pathology ; Oxides/therapeutic use ; Reactive Oxygen Species
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-12 z 12

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies